Drug Profile
OMN 54
Alternative Names: Aneustat; OMN54Latest Information Update: 27 Oct 2021
Price :
$50
*
At a glance
- Originator Genyous Biomed
- Class Antineoplastics
- Mechanism of Action Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 18 Oct 2021 Omnitura Therapeutics and Vancouver Prostate Centre withdraw the phase IIa CAMPAS trial for Prostate cancer (First-line therapy) in Canada (PO, Capsule), prior to enrolment, due to no funding (NCT03495479)
- 09 Sep 2020 Omnitura Therapeutics plans the phase IIa CAMPAS trial for Prostate Cancer in January 2021 (PO, Capsule) (NCT03495479)
- 09 Sep 2020 Omnitura Therapeutics plans the pivotal ADAPT 1 phase IIb/III trial for Prostate cancer (Combination therapy) in late 2020 (PO, Capsule)